Suscribirse

Randomized, Double-Blind, Placebo-Controlled Study of Synbiotic Yogurt Effect on the Health of Children - 24/05/15

Doi : 10.1016/j.jpeds.2015.02.038 
Tamar Ringel-Kulka, MD, MPH 1, , Jonathan B. Kotch, MD, MPH 1, Elizabeth T. Jensen, MPH, PhD 1, 2, Eric Savage, MA 3, David J. Weber, MD, MPH 2, 4
1 Department of Maternal and Child Health, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC 
2 Department of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC 
3 Frank Porter Graham Child Development Institute, The University of North Carolina at Chapel Hill, Chapel Hill, NC 
4 Division of Infectious Diseases, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 

Reprint requests: Tamar Ringel-Kulka, MD, MPH, Department of Maternal and Child Health, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, CB# 7445, Chapel Hill, NC 27599-7445.

Abstract

Objective

To assess the effects of daily consumption of a synbiotic yogurt drink on the health, growth, and quality of life of healthy children 12-48 months of age in out-of-home child care.

Study design

Healthy children attending child care centers were enrolled in a prospective, double-blind, placebo-controlled clinical trial. The intervention was a yogurt drink containing Streptococcus thermophilus, Lactobacillus bulgaricus, and Bifidobacterium animalis subspecies lactis (BB-12) (5 × 109 cfu/100 mL serving), and 1 g of inulin (synbiotic group) vs a similar nonsynbiotic-containing acidified milk drink (placebo group) once daily for 16 weeks. The end points were days of diarrhea, fever, vomiting, symptoms of upper respiratory tract infection, use of antibiotics, physician visits, child care absenteeism, parental work absenteeism, and quality of life (PedsQL 4.0; Mapi Research Trust, Lyon, France).

Results

Compared with placebo (n = 73), children receiving synbiotic (n = 76) had significantly fewer days of reported fever (1.85 vs 1.95, P < .05), significant improvement in social functioning (P < .035; pre-to-end intervention), and school functioning (P < .045; pre-to-mid intervention). More days with ≥3 loose/watery stools were reported in the synbiotic group (P < .05).

Conclusions

Daily supplementation of children's diet with yogurt containing probiotic bacteria BB-12 and inulin significantly reduced days of fever and improved social and school functioning. The increased frequency of bowel movements may be explained by an accelerating effect of BB-12 and inulin on intestinal transit. Further research on the possible benefits of synbiotics on children's health is advised.

Trial registration

ClinicalTrials.gov: NCT00653705.

El texto completo de este artículo está disponible en PDF.

Keyword : BB-12, BMI, CCC, QOL


Esquema


 Supported by General Mills, Inc, to UNC-Chapel Hill. The authors declare no conflicts of interest.


© 2015  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 166 - N° 6

P. 1475 - juin 2015 Regresar al número
Artículo precedente Artículo precedente
  • Long-Term Outcomes of Children with Intermediate Sweat Chloride Values in Infancy
  • Tyler Groves, Paul Robinson, Veronica Wiley, Dominic A. Fitzgerald
| Artículo siguiente Artículo siguiente
  • A Multicenter Study on Childhood Constipation and Fecal Incontinence: Effects on Quality of Life
  • Katja Kovacic, Manu R. Sood, Suzanne Mugie, Carlo Di Lorenzo, Samuel Nurko, Nicole Heinz, Ananthasekar Ponnambalam, Christina Beesley, Rina Sanghavi, Alan H. Silverman

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.